Arcturus Therapeutics Appoints Steve Hughes, M.D., as Chief Development Officer
Dr. Hughes will provide seasoned leadership and direction to Clinical Operations, Clinical Affairs, Clinical Sciences, Data Management/Biometrics, and Drug Safety. As an Officer of the Company, he will serve on the Senior Management Team. His initial focus will be on ARCT-810, a treatment for ornithine transcarbamylase (OTC) deficiency, as it advances into human trials.
“We are at an important stage of the Company’s evolution as we enter 2020,” said Dr. Pad Chivukula, Chief Operating Officer & Chief Scientific Officer of Arcturus Therapeutics. “We are delighted to welcome Dr. Hughes to our team, as he leverages his expertise to provide unique solutions for developing RNA medicines.”
Dr. Hughes stated, “Arcturus is establishing itself as a world leader in the field of intravenously-dosed messenger RNA therapeutics, and over the next few months Arcturus will be transitioning to become a clinical stage pharmaceutical company. I look forward to ushering ARCT-810, a potential mRNA treatment for ornithine transcarbamylase (OTC) deficiency, into the clinic.”
Dr. Hughes has over 20 years of experience building and leading clinical development and medical affairs teams at leading biopharma companies. He has been involved in more than 50 clinical trials with more than 25 drugs across multiple therapeutic areas including cardiovascular, metabolic, neurology, oncology, infectious diseases, rheumatology, ophthalmology and several rare diseases, in the U.S. and globally. Dr. Hughes has also played a key role in the submission of multiple NDA/MAA applications. Most recently he served as the Chief Medical Officer of
Founded in 2013 and based in
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements about our expectations regarding the timing and success of our development efforts. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, collaborations, future financial position, prospects, plans and objectives of management are forward-looking statements. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements and you should not place undue reliance on such forward-looking statements. Actual results and performance could differ materially from those projected in any forward-looking statements as a result of many factors, including without limitation, an inability to develop and market product candidates. Such statements are based on management’s current expectations and involve risks and uncertainties, including those discussed under the heading “Risk Factors” in Arcturus’ Annual Report on Form 20-F for the fiscal year ended
Arcturus Investor Contacts
Source: Arcturus Therapeutics Holdings Inc.